Sign In
Buy BCEL
$0.0900
+0 (+0%)
At Close: Sep 13, 2024
Why Is Atreca (BCEL) Stock Up 85% Today?
08:02am, Thursday, 11'th Jan 2024
Atreca (NASDAQ: BCEL ) stock is rising higher on Thursday following news of a major stake in the clinical-stage biopharmaceutical company from an investment advisor. According to a filing with the Se
BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.
12:53pm, Tuesday, 26'th Dec 2023
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether Atreca, Inc.'s (NASDAQ: BCEL) definitive asset purchase agreement with Immunome, Inc. to sell a colle
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
08:30am, Tuesday, 26'th Dec 2023
CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery pl
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
08:30am, Tuesday, 26'th Dec 2023
SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it
SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
08:00am, Thursday, 21'st Sep 2023
SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
12:24pm, Monday, 14'th Aug 2023
Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.
Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring
04:05pm, Thursday, 10'th Aug 2023
Suspending development of ATRC-101 Cost-saving measures include 40% workforce reduction Focusing on advancing earlier stage ADC candidates and preserving discovery capabilities SAN CARLOS, Calif., Aug
3 Penny Stocks to Catapult You Into the Millionaires' Club
01:03pm, Thursday, 13'th Jul 2023
Tech companies in certain high-growth sectors like semiconductors, AI, and cloud predominantly drove this year's bull market. But while these giants made headlines, many penny stocks continued trading
Atreca, Inc. (BCEL) Q4 2022 Earnings Call Transcript
08:36pm, Wednesday, 29'th Mar 2023
Atreca, Inc. (NASDAQ:BCEL ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Alex Gray - Head of Investor Relations John Orwin - CEO Tito Serafini - Chief Strategy Offic
Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023
05:00pm, Thursday, 23'rd Mar 2023
Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101 Call/webcast to feature updates on the discovery platform and
Why Is Atreca (BCEL) Stock Up Today?
09:47am, Tuesday, 14'th Feb 2023
Atreca (NASDAQ: BCEL ) stock is getting a boost on Tuesday as the company continues a recent rally connected to insider buying. On Monday, shares of BCEL stock jumped nearly 14% after a series of fili
Atreca Locks In A Catalyst In The Oncology Space
11:35am, Wednesday, 01'st Feb 2023
BCEL is set to produce additional data from a phase 1b trial of its antibody ATRC-101 in multiple solid tumor types. Based on previous data, BCEL has refined the patients it enrolls in the trial, whic
Atreca to Present at Upcoming Investor Conferences
04:30pm, Monday, 07'th Nov 2022
SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d
Atreca to Present at Upcoming Investor Conferences
04:05pm, Friday, 09'th Sep 2022
SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique
